Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability
作者:Silong Zhang、Luolong Qing、Ziwei Wang、Yu Zhang、Yuanyuan Li、Huaxiang Fang、Yi Liu、Huan He
DOI:10.1021/acs.jmedchem.2c02006
日期:——
Inhibition of methionine adenosyltransferase 2A (MAT2A) in cancers with a deletion of methylthioadenosine phosphorylase (MTAP) gene leads to synthetic lethality, thus receiving significant interest in the field of precise cancer treatment. Herein, we report the discovery of a tetrahydrobenzo[4,5]imidazo[1,2-a]pyrazine fragment which occupies the MAT2A allosteric pocket. The lead compound 8 exhibited
在甲基硫代腺苷磷酸化酶 (MTAP) 基因缺失的癌症中抑制甲硫氨酸腺苷转移酶 2A (MAT2A) 会导致合成致死,因此在精准癌症治疗领域受到极大关注。在此,我们报告了四氢苯并[4,5]咪唑并[1,2- a ]吡嗪片段的发现,它占据了 MAT2A 变构口袋。先导化合物8表现出极高的抑制 MAT2A 酶活性 (IC 50 = 18 nM) 和 MTAP 无效癌细胞增殖 (IC 50 = 52 nM) 的效力。8具有良好的药代动力学特征,在小鼠中的生物利用度为 116%。更重要的是,引入酰胺基序(28) 到核心结构将血浆药物暴露量从 11 718 提高到 41 192 ng·h·mL –1。28显示出明显优于AG-270 的体内效力,后者正在临床试验中进行评估,并在异种移植 MTAP 耗尽的结肠肿瘤模型中诱导 -52% 的肿瘤消退。